Rethinking cystic fibrosis pathology: The critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation

Free Radical Biology and Medicine

Volumn 30, Issue 12, 2001, Pages 1440-1461

  Hudson, Valerie M ^a  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Antioxidant; CFTR; Cystic fibrosis; Free radicals; Inflammation; Lipid peroxidation; NF B; Nitric oxide (NO); Reduced glutathione (GSH)

Indexed keywords

ANTIOXIDANT; GLUTATHIONE;

ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIOXIDANTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOKINES; DISEASE SUSCEPTIBILITY; DRUG ADMINISTRATION ROUTES; ENDOPEPTIDASES; GENE EXPRESSION REGULATION; GLUTATHIONE; HUMANS; IMMUNE SYSTEM; INFECTION; LUNG; MODELS, BIOLOGICAL; MUCUS; NF-KAPPA B; NITRIC OXIDE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035876878     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(01)00530-5     Document Type: Article

References (358)

1. Glutathione permeability of CFTR
2. Abnormal glutathione transport in cystic fibrosis airway epithelia
3. Early pulmonary inflammation in infants with cystic fibrosis
4. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis
5. Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology
6. Early inflammation is a hallmark of proximal and distal human CF fetal airway xenografts
7. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients
8. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis
9. Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway diseases
10. Activation of NFKB in CF and normal respiratory epithelial cells
11. Effects of CFTR mutations on epithelial cytokine expression
12. Constitutive secretion of IL-8 by cystic fibrosis airway epithelial cells is suppressed by functional CFTR
13. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation
14. Acquisition of Pseudomonas aeruginosa in young infants
15. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening
16. CF microbiology in young children
17. Defective apoptosis of lung cells expressing mutant CFTR after infection with Pseudomonas aeruginosa
18. Nitric oxide synthase activity is elevated in inflammatory lung disease in humans
19. Exhaled nitric oxide in paediatric asthma and cystic fibrosis
20. Increased nitric oxide in the exhaled air of normal human subjects with upper respiratory tract infections
21. Elevated levels of exhaled nitric oxide in bronchiectasis
22. Flow-dependency of exhaled nitric oxide in children with asthma and cystic fibrosis
23. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis
24. Reduced upper airway nitric oxide in cystic fibrosis
25. Airway nitric oxide in asthmatic children and patients with cystic fibrosis
26. Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype
27. Nitrite levels in breath condensate of patients with cystic fibrosis is elevated in contrast to exhaled nitric oxide
28. Normal alveolar epithelial lining fluid contains high levels of glutathione
29. Epithelial permeability, inflammation, and oxidant status in the air spaces of chronic smoker
30. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension
31. Systemic deficiency of glutathione in cystic fibrosis
32. Pulmonary oxidative stress response in young children with cystic fibrosis
33. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress
34. Thiol-based antioxidants
35. Lung glutathione and oxidative stress: Implications in cigarette smoke-induced airway disease
36. Glutathione: In defence of the lung
37. The effects of chronic alcohol abuse on pulmonary glutathione homeostasis
38. The 74th annual meeting president lecture: Pathogenesis and therapy of acute lung injury
39. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis
40. Surface tension, glutathione content and redox ratio of the tracheal aspirate fluid of premature infants with IRDS
41. Increased oxidation of extracellular glutathione by bronchoalveolar inflammatory cells in diffuse fibrosing alveolitis
42. Glutathione deficiency and human immunodeficiency virus infection
43. Alveolar glutathione fluid decreases in asymptomatic HIV-seropositive subjects over time
44. Population, acid-base, and redox properties of N-acetylcysteine conformers
45. Acetylcysteine: A drug that is much more than a mucokinetic
46. Expression of antioxidant enzymes in human inflammatory cells
47. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress
48. Systemic deficiency of glutathione in cystic fibrosis
49. Protection of granulocytes by vitamin E in glutathione synthetase deficiency
50. Glutathione redox system in oxidative lung injury
51. Oxygen-induced lung damage. Relationship to lung mitochondrial glutathione levels
52. Chrysolite-mediated imbalance in the glutathione redox system in the development of pulmonary injury
53. Buthionine sulfoximine-induced glutathione depletion. Its effect on antioxidants, lipid peroxidation and calcium homeostasis in the lung
54. Glutathione transport and impaired antioxidant function in cystic fibrosis
55. Glutathione deficiency in alcoholics: Risk factor for paracetamol hepatotoxicity
56. Mitochondrial glutathione depletion in alcoholic liver disease
57. Glutathione status in liver and plasma during development of biliary cirrhosis after bile duct ligation
58. Effect of liver cirrhosis and age on the glutathione concentration in the plasma, erythrocytes, and gastric mucosa of man
59. Vagal system impairment in human immunodeficiency virus-positive patients with chronic hepatitis C: Does hepatic glutathione deficiency have a pathogenic role?
60. Effect of glutathione depletion on exocyclic adduct levels in the liver DNA of F344 rats
61. Hepatic oxidant injury and glutathione depletion during total parenteral nutrition in weanling rats
62. Biliary excretion in persons with low blood glutathione
63. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat
64. Role of glutathione and oxidative stress in phalloidin-induced cholestasis
65. Glutathione depletion alters hepatocellular high-energy phosphate metabolism
66. N-acetylcysteine decreases severity of acute pancreatitits in mice
67. Pentoxifylline ameliorates cerulein-induced pancreatitits in rats: Role of glutathione and nitric oxide
68. Xenobiotic metabolism, oxidant stress and chronic pancreatitis: Focus on glutathione
69. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione
70. Supplementation of N-acetylcysteine inhibits NFkappaB activation and protects against alloxan-induced diabetes in CD-1 mice
71. Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus
72. Vulnerability to glucose deprivation injury correlates with glutathione levels in astrocytes
73. The effect of acute glutathione treatment on sorbitol level in erythrocytes from diabetic patients
74. Toxicity of low levels of methylglyoxal: Depletion of blood glutathione and adverse effect on glucose tolerance in mice
75. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents
76. Plasma GSH/GSSG affects glucose homeostasis in healthy subjects and non-insulin dependent diabetics
77. Modulation of oxidant status by meloxicam in experimentally induced arthritis
78. Phenytoin-induced glutathione depletion in rat peripheral nerve
79. Deleterious effects of buthionine sulfoximine on cardiac function during continuous endotoxemia
80. Replenishment of glutathione levels improves mucosal function in experimental acute colitis
81. Gastric mucosal damage in experimental diabetes in rats: Role of endogenous glutathione
82. Role of lipid peroxidation and antioxidants in gastric mucosal injury induced by hypoxanthine-xanthine oxidase system in rats
83. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease
84. Low levels of glutathione in endoscopic biopsies of patients with Crohn's colitis: The role of malnutrition
85. Gastrointestinal surface protection and mucosa reconditioning
86. Glutathione plays a role in the chick intestinal calcium absorption
87. Differential reconstitution of mitochondrial respiratory chain activity and plasma redox state by cysteine and ornithine in a model of cancer cachexia
88. Growth retardation and cysteine deficiency in gamma-glutamyl transpeptidase-deficient mice
89. Cysteine and glutathione in catabolic conditions and immunological dysfunction
90. Oedematous malnutrition
91. Mechanism of interaction of vitamin E and glutathione in the protection against lipid peroxidation
92. Glutathione depletion induces giant DNA and high-molecular-weight DNA fragmentation associated with apoptosis through lipid peroxidation and protein kinase C activation in C6 glioma cells
93. Glutathione-dependent factors and inhibition of rat liver microsomal lipid peroxidation
94. Kidney injury induced by lipid peroxide produced by vitamin E deficiency and GSH depletion in rats
95. Administration of glutathione and lipid peroxidation induced during fasting
96. Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL: In vitro and in vivo studies
97. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr (-/-) mice
98. Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1
99. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis
100. Oxidant-protease interaction in the lung: Prospects for antioxidant therapy
101. Recombinant secretory leukoprotease inhibitor augments gluathione levels in lung epithelial lining fluid
102. Comparative loss of activity of recombinant secretory leukoprotease inhibitor and alpha 1-protease inhibitor caused by different forms of oxidative streaa
103. Therapeutic approaches to cystic fibrosis
104. 2) increases the steady-state mRNA levels of collagenase/MMP-1 in human dermal fibroblasts
105. Ascorbic acid prevents oxidative stress in glutathione deficient mice: Effects on lung type 2 cell lamellar bodies, lung surfactant, and skeletal muscle
106. Glutathione metabolism in newborns: Evidence for glutathione deficiency in plasma, bronchoalveolar lavage fluid, and lymphocytes in prematures
107. Glutathione modulates lipid composition of human colon derived HT-29 cells
108. Free radical induced respiratory muscle dysfunction
109. Competition for glutathione precursors between the immune system and the skeletal muscle: Pathogenesis of chronic fatigue syndrome
110. Tissue distribution of multidrug resistance protein
111. Frequent paracetamol use and asthma in adults
112. Neutrophil antioxidant capacity during the respiratory burst: Loss of glutathione induced by chloramines
113. Gutathione metabolism in activated human neutrophils: Stimulation of glutathione synthesis and consumption of glutathione by reactive oxygen species
114. Inhibition of glutathione reductase by isoproterenol oxidation products
115. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage
116. Increase in gamma-glutamyltransferase by glutathione depletion in rat type II pneumocytes
117. An investigation of the role of glutathione in increased epithelial permeability induced by cigarette smoke in vivo and in vitro
118. Molecular mechanisms of neutrophil-endothelial cell adhesion induced by redox imbalance
119. Destabilization and denaturation of cellular protein by glutathione depletion
120. HSP70 induction in the brain following ethanol administration in the rat: Regulation by glutathione redox state
121. Activation of heat shock factor by alkylating agents is triggered by glutathione depletion and oxidation of protein thiols
122. The level of intracellular glutathione is a key regulator for the induction of stress-activated signal transduction pathways including Jun N-terminal protein kinases and p38 kinase by alkylating agents
123. Glutathione redox potential in response to differentiation and enzyme inducers
124. Glutathione depletion-induced thymidylate insufficiency for DNA repair synthesis
125. Effect of nonprotein thiols on protein synthesis in isolated rat hepatocytes
126. Effects of dexamethasone on lung protein turnover
127. Protein synthesis in growing-rat tissues. II. Polyribosome concentration of brain and liver as a function of age
128. Effect of chronic glutathione deficiency on rat lung mitochondrial function
129. Accumulation of DNA damage in the organs of mice deficient in gamma-glutamyltranspeptidase
130. Effects of glutathione depletion on oxidant-induced endothelial cell injury
131. N-acetylcysteine protects epithelial cells against the antioxidant imbalance due to Clostridium difficile toxins
132. Cystine starvation induces reversible large-body formation from nuclear bodies in T24 cells
133. Glutathione oxidation is associated with altered microtubule function and disrupted fertilization in mature hamster oocytes
134. Ascorbic acid prevents oxidative stress in glutathione-deficient mice: Effects on lung type 2 lamellar bodies, lung surfactant, and skeletal muscle
135. Compartmentation of glutathione: Implications for the study of toxicity and disease
136. Regulation of mucociliary clearance in health and disease
137. Mucus-controlling agents: Past and present
138. Effects of drugs on mucus clearance
139. Mucolytics and the critically ill patient: Help or hindrance?
140. Rationale of airway clearance
141. Residual oil fly ash induces cytotoxicity and mucin secretion by guinea pig tracheal epithelial cells via an oxidant-mediated mechanism
142. Activation of NF-κB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aerugionosa-induced mucin overproduction in epithelial cells
143. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns
144. Modification of transepithelial ion transport in human cultured bronchial epithelial cells by interferon-gamma
145. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cell lines
146. A new pathway of nitric oxide cylclic GMP signaling involving s-nitrosoglutathione
147. Neutrophil elastase induces MUC5AC messenger RNA expression by an oxidant-dependent mechanism
148. Glutathione downregulates the phosphorylation of I κ-B: Autoloop regulation of the NF-κ B-mediated expression of NF-κ B subunits by TNF-α in mouse vascular endothelial cells
149. Modulation of lymphocyte functions and immune responses by cysteine and cysteine derivatives
150. Glutathione regulation of tumor necrosis factor-α-induced NF-κ B activation in skeletal muscle-derived L6 cells
151. Intracellular glutathione redox status modulates MCP-1 expression in pulmonary granulomatous vasculitis
152. Intrastriatal dopamine injection induces apoptosis through oxidation-involved activation of transcription factors AP-1 and NF-κB in rats
153. Antioxidant/pro-oxidant equilibrium regulates HIF-1alpha and NF-κB redox sensitivity: Evidence for inhibition by glutathione oxidation in alveolar epithelial cells
154. Redox regulation of lipopolysaccharide (LPS)-induced interleukin-8 (IL-8) gene expression mediated by NF κ B and AP-1 in human astrocytoma U373 cells
155. Regulation of redox glutathione levels and gene transcription in lung inflammation: Therapeutic approaches
156. The role of nuclear factor-κ B in pulmonary diseases
157. CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses
158. Intracellular GSH content and HIV replication in human macrophages
159. Glutathione inhibits HIV replication by acting at the late stages of the virus life cycle
160. Thiol regulation of the production of TNF-α, IL-6 and IL-8 by human alveolar macrophages
161. Regulation by intracellular glutathione of TNF-α-induced p38 MAP kinase activation and RANTES production by human pulmonary vascular endothelial cells
162. Suppressive effects of intracellular glutathione on hydroxyl radical production induced by tumor necrosis factor
163. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production
164. Modulation of IL-1-induced chemokine expression in human mesangial cells through alterations in redox status
165. Treatment with glutathione precursor decreases cytokine activity
166. Redox regulation of chemokine receptor expression
167. Induction of proinflammatory cytokines in human epidermal carcinoma cells by in vitro ultraviolet A1 irradiation
168. Modulation of silica-induced lung injury by reducing lung non-protein sulfhydryls with buthionine sulfoximine
169. The protective role of endogenous gluathione in carrageenan-induced pleurisy in the rat
170. Inhibition of neutral magnesium-dependent sphingomyelinase by glutathione
171. Thiol-mediated redox regulation of neutrophil apoptosis
172. Apoptosis induced by chelation of intracellular zinc is associated with depletion of cellular reduced glutathione level in rat hepatocytes
173. GSH extrusion and the mitochondrial pathway of apoptotic signaling
174. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor
175. Direct evidence for glutathione as mediator of apoptosis in neuronal cells
176. Inflammation, lipids, and free radicals: Lessons learned from the atherogenic process
177. Glutathione (GSH) and the toxicity of oxidised low-density lipoprotein to human monocyte-macrophages
178. Thiol depletion induces apoptosis in cultured lung fibroblasts
179. Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by mephalan (L-phenylalanine mustard) in human colorectal cancer cells
180. Ebselen induces apoptosis in HepG(2) cells through rapid depletion of intracellular thiols
181. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion
182. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: Possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state
183. Inhibition of human polymorphonuclear leukocyte function by 2-cyclohexene-1-one: A role for glutathione in cell activation
184. Effects of selenium on polymorphonuclear leukocyte function in goats
185. Changes in the levels of glutathione in phagocytosing human neutrophils
186. Glutathione-dependent modulation of exhausting exercise-induced changes in neutrophil function of rats
187. Mercuric chloride down-regulates T cell interferon-gamma production in brown Norway but not in Lewis rats; role of glutathione
188. Glutathione modulates activation-dependent proliferation of human peripheral blood lymphocyte populations without regulating their activated function
189. The glutathione depleting agent diethylmaleate prolongs renal allograft survival
190. Glutathione depletion in rats impairs T-cell and macrophage immune function
191. Optimal NF κ B mediated transcriptional responses to Jurkat T cells exposed to oxidative stress are dependent on intracellular glutathione and costimulatory signals
192. Induction of apoptosis in human T-cells by methyl mercury: Temporal relationship between mitochondiral dysfunction and loss of reductive reserve
193. Markedly distrubed glutathione reodx status in CD45RA+CD4+ lymphocytes in human immunodeficiency virus type 1 infection is associated with selective depletion of this lymphocyte subset
194. Glutathione deficiency is asociated with impaired survival in HIV disease
195. Lymphocyte proliferation in glutathione-depleted lymphocytes: Direct relationship between glutathione availability and the proliferative response
196. Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis
197. Comparative study of intracellular glutathione content in rat lymphocyte cultures treated with 2-mercaptoethanol and interleukin-2
198. Interleukin-2 mRNA expression, lymphokine production and DNA synthesis in glutathione-depleted rats
199. Reversal of multiple-site tumor cell-induced immunosuppression by specific cytokines and pharmacological agents
200. Upregulation of intracellular glutathione by fibroblast-derived factor(s): Enhanced survival of activated T cells in the presence of low Bcl-2
201. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase
202. Glutathione and lymphocyte activation: A function of ageing and auto-immune disease
203. Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis
204. Evidence for glutathione involvement in platelet-derived growth-factor-mediated signal
205. Depletion of glutathione by benzo(a)pyrene metabolites, ionomycin, thatpsigargin, and phorbol myristate in human peripheral blood mononuclear cells
206. Regulation by glutathione of the effect of lymphokines on differentiation of primary activated lymphocytes. Influence of glutathione on cytotoxic activity of CD3-AK-
207. Differential effects of glutathione depletion on T cell subsets
208. Dichotomy of glutathione regulation of the activation of resting and preactivated lymphocytes
209. Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine
210. Regulation by glutathione of the activation and differentiation of IL-4-dependent activated killer cells
211. Zinc-controlled Th1/Th2 switch significantly determines development of disease
212. Cysteine, glutathione (GSH) and zinc and copper ions together are effective, natural, intracellular inhibitors of (AIDS) viruses
213. Modern diets and diseases: NO-zinc balance. Under Th1, zinc and nitorgen monoxide (NO) collectively protect against viruses, AIDS, autoimmunity, diabetes, allergies, asthma, infectious diseases, atherosclerosis and cancer
214. Chronic pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th1 responding C3H/HeN mice
215. Regulation of iNOS mRNA levels in endothelial cells by glutathione, a double-edged sword
216. Diethylmaleate and buthionine sulfoximine, glutathione-depleting agents, differentially inhibit expression of inducible nitric oxide synthase in endotoxemic mice
217. Expression of inducible nitric oxide synthase in endotoxemic rat hepatocytes is dependent on the cellular glutathione status
218. Redox imbalance differentially inhibits lipopolysaccharide-induced macrophage activation in the mouse liver
219. NO elicits prolonged relaxation of bovine pulmonary arteries via endogenous peroynitrite generation
220. The chemistry of the S-nitrosoglutathione/glutathione system
221. Role of glutathione in nitric oxide-dependent regulation of energy metabolism in rat hepatoma cells
222. Nitric oxide-mediated mitochondrial damage in the brain: Mechanisms and implications for neurodegenerative diseases
223. Nitric oxide-dependent induction of glutathione synthesis through increased expression of gamma-glutamylcysteine synthetase
224. Stimulation of cystine uptake by nitric oxide: Regulation of endothelial cell glutathione levels
225. Interleukin-1-induced nitric oxide production modulates glutathione synthesis in cultured rat hepatocytes
226. Down-regulation of renal glutathione synthesis by systemic nitric oxide synthesis inhibition in spontaneously hypertensive rats
227. Ratio of S-nitrosohomocyst(e)ine or other thiols determines neurotoxicity in rat cerebrocortical cultures
228. Nitric oxide can function as either a killer molecule or an antiapoptotic effector in cardiomyocytes
229. Intracellular redox state determines whether nitric oxide is toxic or protective to rat oligodendrocytes in culture
230. The redox pathway of S-nitrisoglutathione, glutathione and nitric oxide in cell to neuron communications
231. Glutathione levels determine apoptosis in macrophages
232. Reduced glutathione prevents nitric oxide-induced apoptosis in vascular smooth muscle cells
233. Synergistic depletion of astrocytic glutathione by glucose deprivation and peroxynitrite: Correlation with mitochondrial dysfunction and subsequent cell death
234. Role of mitogen-activated protein kinases in S-nitrosoglutathione-induced macrophage apoptosis
235. Differential cytostatic effects of NO donors and NO producing cells
236. Glutathione protects macrophages and Leishmania major against nitric oxide-mediated cytotoxicity
237. Superoxide-mediated decomposition of biological S-nitrosothiols
238. NO+, NO, and NO- donation by S-nitrosothiols: Implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation
239. Superoxide released from neutrophils causes a reduction in nitric oxide gas
240. Membrane effects of nitrite-induced oxidation of human red blood cells
241. Nitric oxide as a neurotransmitter in human airways
242. Relaxation of human bronchial smooth muscle by S-nitrosothiols in vitro
243. Nitric oxide activates chloride currents in human lung epithelial cells
244. Activation of CFTR chloride current by nitric oxide in human T lymphocytes
245. Ciliostimulatory effects mediated by nitric oxide
246. Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation
247. Oxidative stress in cystic fibrosis: Does it occur and does it matter?
248. Enhanced oxidative damage in cystic fibrosis patients
249. Natural history of liver disease in cystic fibrosis
250. Hepatobiliary and pancreatic manifestations of cystic fibrosis: MR imaging appearances
251. Liver disease and common-bile-duct stenosis in cystic fibrosis
252. Islet autoantibodies and insulin dependent diabetes mellitus in cystic fibrosis
253. Intestinal inflammation in cystic fibrosis
254. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients
255. Tumor necrosis-factor-alpha, resting energy expenditure and cachexia in cystic fibrosis
256. Musculoskeletal involvement in cystic fibrosis
257. Arthropathies of cystic fibrosis: Case reports and review of the literature
258. Peripheral nerve dysfunction in adult patients with cystic fibrosis
259. Partial CFTR genotyping and characterization of cystic fibrosis patients with myocardial fibrosis and necrosis
260. Oxygen free radicals and antioxidants in cystic fibrosis: The concept of an oxidant-antioxidant imbalance
261. Lipid peroxidation and antioxidant defenses in cystic fibrosis patients
262. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis
263. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild disease suggest ongoing infection and inflammation
264. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis
265. Epithelial cell damage is induced by neutrophil-derived, not pseudomonas-derived, proteases in cystic fibrosis sputum
266. Therapeutic approaches to cystic fibrosis
267. Pulmonary surfactant in cystic fibrosis
268. Respiratory and peripheral muscle function in cystic fibrosis
269. Peripheral muscle weakness and exercise capacity in children with cystic fibrosis
270. Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride
271. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum
272. Ultrastructure of airway epithelial cell membranes among patients with cystic fibrosis
273. Human airway epithelial tight junctions
274. Role of CFTR in airway disease
275. DNA fragmentation is a feature of cystic fibrosis epithelial cells: A disease with inappropriate apoptosis?
276. Bronchial secretions and bronchial mucosa in children with cystic fibrosis: Comparison of bronchoscopic, biochemical, bacteriological, microscopic and ultrastructural findings
277. Oxidative damage to DNA in patients with cystic fibrosis
278. Genistein inhibits constitutive and inducible NFκB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells
279. Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients
280. Desensitization of neutrophil responses by systemic interleukin 8 in cystic fibrosis
281. Altered respiratory epithelial cell cytokine production in cystic fibrosis
282. Serum interleukin-1 alpha and soluble interleukin-2 receptor concentrations in cystic fibrosis
283. Plasma interleukin-1 alpha and beta, tumor necrosis factor-α, and lipopolysaccharride concentrations during pulmonary exacerbations of cystic fibrosis
284. Regulation of cytokine secretion by cystic fibrosis airway epithelial cells
285. Inflammation and CFTR: Might neutrophils be the key in cystic fibrosis?
286. Neutrophil adhesion molecule surface expression and responsiveness in cystic fibrosis
287. Flow-cytometric evaluation of oxidative burst in phagocytic cells of children with cystic fibrosis
288. Increased antigen-specific Th2-response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis
289. Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation
290. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes
291. Functional immunoregulatory T-cell abnormalities in cystic fibrosis patients
292. An increase in gamma-delta T-lymphocytes in the peripheral blood of cystic fibrosis patients
293. Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR)
294. T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis
295. Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease
296. T cell cytotoxicity in cystic fibrosis: Relationship to pulmonary status
297. Functional immunoregulatory T-cell abnormalities in cystic fibrosis patients
298. Decreased T helper cell function in patients with cystic fibrosis
299. B-lymphocyte function in cystic fibrosis
300. Lack of inducible nitric oxide synthase in bronchial epithelium: A possible mechanism of susceptibility to infection in cystic fibrosis
301. Neutrophils enhance expression of inducible nitric oxide synthase in human normal but not cystic fibrosis bronchial epithelial cells
302. Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression
303. Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function
304. Total sputum nitrate plus nitrite is raised during acute pulmonary infection in cystic fibrosis
305. Nitric oxide metabolites in cystic fibrosis lung disease
306. Nitric oxide and interleukin-8 as inflammatory components of cystic fibrosis
307. Superoxide released from neutrophils causes a reduction in nitric oxide gas
308. Regulation of iNOS expression and glutathione levels in rat liver by oxygen tension
309. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung
310. Expression of γ-glutamylcysteine synthetase (γ-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs
311. Pulmonary oxidative stress response in young children with cystic fibrosis
312. Erythrocyte glutathione S transferase as a marker of oxidative stress at birth
313. Determination of low-molecular-mass antioxidant concentrations in human respiratory tract lining fluids
314. Selenium and glutathione peroxidase levels in cystic fibrosis
315. Absence of modifications of the enzyme defense system against oxygen toxicity in cystic fibrosis
316. Transfection of wild-type CFTR into cystic fibrosis lymphocytes restores chloride conductance at G1 of the cell cycle
317. Antisense oligonucleotides to CFTR confer a cystic fibrosis phenotype on B lymphocytes
318. Human lymphocytes transcribe the cystic fibrosis transmembrane conductance regulator gene and exhibit CF-defective cAP-regulated chloride current
319. A multidrug-resistance protein (MRP)-like transmembrane pump is highly expressed by resting murine T helper (Th) 2, but not Th1 cells, and is induced to equal expression levels in Th1 and Th2 cells after antigenic stimulation in vivo
320. Expression of MDR1 and MRP in the normal B-cell homologue of B-cell chronic lymphocytic leukemia
321. Oral glutathione increases tissue glutathione in rats
322. Expression of the multidrug resistance-associated protein (MRP) mRNA and protein in normal peripheral blood and bone marrow haemopoietic cells
323. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2
324. Enhancement of neutrophil response by SH-containing compounds: Modulation of superoxide and hydrogen peroxide production
325. Inhibition of neutrophil function by hydrogen peroxide. Effect of SH-group-containing compounds
326. Peroxides inhibit the glutathione S-conjugate pump
327. Lymphocyte glutathione levels in children with cystic fibrosis
328. Glutathione metabolism and glutathione S-conjugate export ATPase
329. Investigation of the transport of intact glutathione in human and rat type II pneumocytes
330. Efflux of reduced glutathione after exposure of human lung epithelial cells to crocidolite asbestos
331. Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report
332. Cysteine and glutathione deficiency in AIDS patients: A rationale for the treatment with N-acetyl-cysteine
333. Inhibition of HIV-1 replication and NF-kappa B activity by cysteine and cysteine donors
334. Treatment of obstructive airway disease with a cysteine donor protein supplement: A case report
335. Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis
336. Augmentation of the glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione
337. Reversal of the glutathione deficiency in the lower respiratory tract of HIV-seropositive individuals by glutathione aerosol therapy
338. Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment
339. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis
340. Nebulized glutathione induces bronchoconstriction in patients with mild asthma
341. Glutathione in bronchial hyperresponsiveness
342. Glutathione in the upper respiratory tract
343. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis
344. Reduced intravenous glutathione in the treatment of early Parkinson's disease
345. Glutathione transport system in human small intestine epithelial cells
346. Absorption of glutathione from the gastro-intestinal tract
347. Effect of orally administered glutathione on glutathione levels in some organs of rats: Role of specific transporters
348. Bioavailability of dietary glutathione: Effect on plasma concentration
349. In vitro evaluation of the ability of glutathione to suppress the inflammatory cell derived oxidant burden in respiratory epithelial lining fluid of individuals with cystic fibrosis
350. Cough induced by low pH
351. Lung uptake of liposome-entrapped glutathione after intratracheal administration
352. Liposomes and bronchoalveolar lavage fluid: Release of vesicle-entrapped glutathione
353. Distribution studies of liposome-encapsulated glutathione administered to the lung
354. The osmolarity of solutions used in nebulisation